

FORM PTO-1390 (REV 11-2000)		U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 3557-13	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U S APPLICATION NO (If known, see 37 C F R 1.5) 10/089370 Unknown	
INTERNATIONAL APPLICATION NO. PCT/EP00/09839		INTERNATIONAL FILING DATE 7 October 2000		PRIORITY DATE CLAIMED 11 October 1999	
TITLE OF INVENTION PLANT PRPP AMIDOTRANSFERASE					
APPLICANT(S) FOR DO/EO/US LERCHL et al					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The U.S. has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input checked="" type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input checked="" type="checkbox"/> A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11 To 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information. Paper copy of sequence listing 					

SIGNATURE

36,663

March 29, 2002
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Lerchl et al.

Atty. Ref.: **3557-13**

Serial No. **Unassigned**

Group: **Unassigned**

National Phase of: **PCT/EP00/09839**

International Filing Date: **7 October 2000**

Filed: **March 29, 2002**

Examiner: **Unassigned**

For: **PLANT PRPP AMIDOTRANSFERASE**

* * * * *

March 29, 2002

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Prior to calculation of the filing fee and in order to place the above identified application in better condition for examination, please amend as follows:

IN THE SPECIFICATION

Page 1, after the title insert the following:

-- This application is the US national phase of international application PCT/EP00/09839 filed 7 October 2000, which designated the U.S. --.

Insert the attached Sequence Listing in place of the originally-filed Sequence Listing.

IN THE CLAIMS

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

Lerchl et al.
Serial No. **Unassigned**

REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added. A separate Statement to this effect is attached.

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



B. J. Sadoff

Reg. No. 36,663

BJS:bjs

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

Lerchl et al.
Serial No. **Unassigned**

VERSION WITH MARKINGS TO SHOW CHANGES MADE

6. (Amended) The use of a DNA sequence as claimed in claim 1 [or 2] for introduction into pro- or eukaryotic cells, this sequence optionally being linked to control elements which ensure transcription and translation in the cells and leading to the expression of a translatable mRNA which causes the synthesis of a plant PRPP amidotransferase.

7. (Amended) The use of a DNA sequence as claimed in claim 1 [or 2] for generating an assay system for identifying herbicidally active plant PRPP amidotransferase inhibitors.

8. (Amended) A method of finding herbicidally active substances which inhibit the activity of the plant PRPP amidotransferase, which comprises preparing, in a first step, PRPP amidotransferase using a DNA sequence as claimed in claim 1 [or 2] and measuring, in a second step, the activity of the plant PRPP amidotransferase in the presence of a test substance.

11. (Amended) An assay system based on the expression of a DNA sequence SEQ-ID No. 1 or SEQ-ID No.9 as claimed in claim 1 [or 2] for identifying herbicidally active plant PRPP amidotransferase inhibitors.

14. (Amended) A plant PRPP amidotransferase inhibitor identified using an assay system as claimed in claim 11 [or 12].

15. (Amended) An inhibitor as claimed in claim 13 [or 14] for use as herbicide.

Plant PRPP amidotransferase

The present invention relates to the identification of plant PRPP
5 amidotransferase (phosphoribosyl-pyrophosphate amidotransferase,
E.C. 2.4.2.14) as novel target for herbicidal active ingredients.
The present invention furthermore relates to DNA sequences
encoding a polypeptide with PRPP amidotransferase activity.
Moreover, the invention relates to the use of a nucleic acid
10 encoding a protein with PRPP amidotransferase activity which
originates from plants for generating an assay system for
identifying herbicidally active PRPP amidotransferase inhibitors
and to plant PRPP amidotransferase identified using this assay
system. The invention furthermore relates to the use of the
15 nucleic acid SEQ-ID No. 1 or SEQ-ID No. 3 encoding plant PRPP
amidotransferase for the generation of plants with an increased
resistance to PRPP amidotransferase inhibitors and for the
generation of plants with a modified purine nucleotide content.
Moreover, the invention relates to a method of eliminating
20 undesired vegetation, where the plants to be eliminated are
treated with a compound which binds specifically to PRPP
amidotransferase encoded by a DNA sequence SEQ-ID No 1 or a DNA
sequence which hybridizes with this DNA sequence, and inhibits
its function.

25

Plants are capable of synthesizing their cell components from
carbon dioxide, water and inorganic salts.

This process is only possible by exploiting biochemical reactions
30 for synthesizing organic substances. Nucleotides are synthesized
de novo in plants. Being components of the nucleic acids, they
are particularly important. Covalently bound, nucleotides
activate carbohydrates for polysaccharide biosynthesis. They
furthermore activate head groups for lipid biosynthesis.
35 Nucleotides are involved in virtually all metabolic pathways.
Nucleoside triphosphates, especially ATP, drive most of the
energy-requiring reactions of the cell. Adenine nucleotides are
additionally also found as components in essential factors such
as coenzyme A and in nicotinamide and flavin coenzymes, which are
40 involved in a large number of cellular reactions. The coupled
hydrolysis of guanosine-5'-triphosphate (GTP) defines a direction
of reaction for various cellular processes such as protein
translation, assembly of microtubuli, vesicular transport, signal
transduction and cell division. Furthermore, nucleotides
45 constitute the starting metabolites for the biosynthesis of

0050/50796

2

methylxanthines such as caffeine and theobromine in the plant family of the Rubiaceae and Theaceae.

Genes which encode PRPP amidotransferase have been isolated from
5 a variety of organisms.

cDNAs which encode PRPP amidotransferase have been isolated and characterized from various bacterial, animal and vegetable organisms. Plant PRPP amidotransferase cDNAs have been isolated
10 via complementation of *E. coli* purF mutants and via DNA hybridization techniques from *Glycine max*, *Vigna aconitifolia* and from *Arabidopsis thaliana* (Ito et al., Plant Molecular Biology 26(1994), 529-533; Kim et al., The Plant Journal 7(1995), 77-86). Sequence homology suggests that the encoded enzymes as well as
15 the *E. coli* PRPP amidotransferase contain 4Fe-4S clusters. The plant PRPP amidotransferase amino acid sequences, which in comparison with *E. coli* are extended at the N terminus, show similarity to plastid signal sequences.

20 Several PRPP amidotransferase isoenzymes which are expressed differentially are found in plants. The RNA for *Arabidopsis thaliana* AtATase1, for example, accumulates preferentially in the roots, while the AtATase2 transcripts are found predominantly in young leaves and flowers (Ito et al., Plant Molecular Biology
25 26(1994), 529-533). In *Vigna aconitifolia*, a PRPP amidotransferase RNA accumulates mainly in root nodules and is induced in root tissues by L-Glutamine (Kim et al., The Plant Journal 7(1995), 77-86).

30 Since plants depend on an effective nucleotide metabolism, it can be assumed that the enzymes which are involved in nucleotide biosynthesis are suitable as target for herbicides. Thus, there have already been described active ingredients which inhibit *de novo* purine biosynthesis in plants. An example which may be
35 mentioned is the natural substance hydanthocidin, which, after phosphorylation *in planta* inhibits adenylosuccinate synthetase (ASS); (Siehl et al., Plant Physiol. 110(1996), 753-758).

Inhibitors for enzymes of purine biosynthesis are, moreover, also
40 known for their pharmacological action in animals and microorganisms: folate analogs inhibit, inter alia, the enzyme GAR transformylase and have an antiproliferative, antiinflammatory and immunosuppressant action. Mycophenolic acid (MPA), an IMP dehydrogenase inhibitor in the GMP synthetic
45 pathway, has an antimicrobial, antiviral and immunosuppressant action (Kitchin et al, Journal of the American Academy of

0050/50796

3

Dermatology 37(1997), 445-449).

Bacterial PRPP amidotransferase can be inhibited for example by glutamine antagonists such as, for example, azaserine,
5 6-diazo-5-oxo-L-norleucine (DON) or L-2-amino-4-oxo-5-chloropentanoic acid and by mercaptopurine and thioguanosine. Glutamine antagonists are not specific to PRPP amidotransferase and also affect other purine biosynthesis enzymes, such as formylglycinamidine ribotide synthase. The
10 efficacy of glutamine antagonists on plant PRPP amidotransferase is still to be proven.

It is an object of the present invention to provide proof that PRPP amidotransferase in plants is a suitable herbicidal target,
15 to isolate a complete plant cDNA encoding the enzyme PRPP amidotransferase and functionally express it in bacterial or eukaryotic cells, and to produce an efficient and simple PRPP amidotransferase assay system for carrying out inhibitor-enzyme binding studies.

20 We have found that this object is achieved by the isolation of genes which encode the plant enzyme PRPP amidotransferase, the generation of PRPP amidotransferase antisense constructs, and the functional expression of PRPP amidotransferase in bacterial or
25 eukaryotic cells.

It is an object of the present invention to isolate full-length cDNAs encoding functional PRPP amidotransferase (E.C.2.4.2.14) from tobacco (*Nicotiana tabacum*).

30 A first subject-matter of the present invention is a DNA sequence SEQ-ID NO. 1 or SEQ-ID NO. 3 containing the encoding region of a plant PRPP amidotransferase from tobacco, see Example 1.

35 Another subject-matter of the invention is DNA sequences which are derived from SEQ-ID NO. 1 or SEQ-ID NO. 3 or which hybridize with one of these sequences and which encode a protein which has the biological activity of a PRPP amidotransferase.

40 Tobacco plants of the line *Nicotiana tabacum* cv. Samsun NN which carry a PRPP amidotransferase antisense construct have been characterized in greater detail. The plants show different degrees of retarded growth and bleaching of the leaves. The transgenic lines and the progeny of the 1st and 2nd generation
45 showed a reduced growth in soil. Using Northern hybridization, it was detected that the RNA quantity of PRPP amidotransferase was reduced in plants with reduced growth compared with the wild

0050/50796

4

type. Furthermore, measurement of the enzyme activity detected that the amount of PRPP amidotransferase activity was reduced in the transgenic lines compared with wild-type plants, see Example 7. Growth retardation and the reduction in PRPP amidotransferase activity correlate. This clear connection identifies PRPP amidotransferase for the first time unambiguously as suitable target protein for herbicidal active ingredients.

To be able to find efficient inhibitors of plant PRPP amidotransferase, it is necessary to provide suitable assay systems with which inhibitor/enzyme binding studies can be carried out. To this end, for example, the complete cDNA sequence of tobacco PRPP amidotransferase is cloned into an expression vector (pQE, Qiagen) and overexpressed in E. coli, see Example 2.

Alternatively, however, it is possible to express the expression cassette containing a DNA sequence of SEQ-ID No. 1 or SEQ-ID NO. 3 for example in other bacteria, in yeasts, fungi, algae, plant cells, insect cells or mammalian cells, see Example 4.

The PRPP amidotransferase protein which is expressed with the aid of the expression cassette according to the invention is particularly suitable for finding inhibitors which are specific to PRPP amidotransferase.

To this end, for example, the plant PRPP amidotransferase can be employed in an enzyme assay in which the PRPP amidotransferase activity is determined in the presence and absence of the active ingredient to be tested. A comparison of the two activity determinations allows a qualitative and quantitative statement to be made on the inhibitory behavior of the active ingredient to be tested, see Example 3.

The assay system according to the invention allows a multiplicity of chemicals to be tested rapidly and simply for herbicidal properties. Using this method, substances with a potent action can be selected specifically and reproducibly from amongst a large number of substances, in order that further in-depth tests with which the skilled worker is familiar are carried out subsequently with these substances.

The invention furthermore relates to a method of identifying herbicidally active substances which inhibit the PRPP amidotransferase activity in plants, with the following steps:

45

6

Herbicidally active PRPP amidotransferase inhibitors can be employed as defoliant, desiccants, haulm killers and, in particular, as herbicides. Weeds in the widest sense are to be understood as meaning all plants which grow in locations where
5 they are undesired. Whether the active ingredients found with the aid of the assay system according to the invention act as total or selective herbicides depends, inter alia, on the quantity applied.

10 Herbicidally active PRPP amidotransferase inhibitors can be used, for example, against the following weeds:

Dicotyledonous weeds of the genera:

Sinapis, Lepidium, Galium, Stellaria, Matricaria, Anthemis,
15 Galinsoga, Chenopodium, Urtica, Senecio, Amaranthus, Portulaca, Xanthium, Convolvulus, Ipomoea, Polygonum, Sesbania, Ambrosia, Cirsium, Carduus, Sonchus, Solanum, Rorippa, Rotala, Lindernia, Lamium, Veronica, Abutilon, Emex, Datura, Viola, Galeopsis, Papaver, Centaurea, Trifolium, Ranunculus, Taraxacum.

20

Monocotyledonous weeds of the genera:

Echinochloa, Setaria, Panicum, Digitaria, Phleum, Poa, Festuca, Eleusine, Brachiaria, Lolium, Bromus, Avena, Cyperus, Sorghum, Agropyron, Cynodon, Monochoria, Fimbristylis, Sagittaria,
25 Eleocharis, Scirpus, Paspalum, Ischaemum, Sphenoclea, Dactyloctenium, Agrostis, Alopecurus, Apera.

Subject-matter of the invention are also expression cassettes whose sequence encodes a tobacco PRPP amidotransferase or its
30 functional equivalent. The nucleic acid sequence can be, for example, a DNA or a cDNA sequence.

In addition, the expression cassettes according to the invention comprise regulatory nucleic acid sequences which govern the
35 expression of the encoding sequence in the host cell. In accordance with a preferred embodiment, an expression cassette according to the invention encompasses upstream, i.e. at the 5' end of the encoding sequence, a promoter, and downstream, i.e. at the 3' end, a polyadenylation signal and, if appropriate, other
40 regulatory elements which are operatively linked to the encoding sequence for the PRPP amidotransferase gene, which sequence lies between the promoter and the polyadenylation signal. Operative linkage is to be understood as meaning the sequential arrangement of promoter, encoding sequence, terminator and, if appropriate,
45 other regulatory elements in such a manner that each of the

0050/50796

7

regulatory elements can function as intended when the encoding sequence is expressed.

An expression cassette according to the invention is generated by
 5 fusing a suitable promoter with a suitable PRPP amidotransferase
 DNA sequence and a polyadenylation signal using customary
 recombination and cloning techniques as they are described, for
 example, by T. Maniatis, E.F. Fritsch and J. Sambrook, Molecular
 Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold
 10 Spring Harbor, NY (1989) and by T.J. Silhavy, M.L. Berman and
 L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor
 Laboratory, Cold Spring Harbor, NY (1984) and by Ausubel, F.M. et
 al., Current Protocols in Molecular Biology, Greene Publishing
 Assoc. and Wiley-Interscience (1987).

15 Subject-matter of the invention are also functionally equivalent
 DNA sequences which encode a PRPP amidotransferase gene and which
 show a sequence homology with the DNA sequence SEQ-ID No. 1 or
 SEQ-ID No. 3 of 40 to 100%, based on the total length of the DNA
 20 sequence.

Preferred subject-matter of the invention are functionally
 equivalent DNA sequences which encode a PRPP amidotransferase
 gene and which show a sequence homology with the DNA sequence
 25 SEQ-ID No. 1 or SEQ-ID No. 3 of 60 to 100%, based on the total
 length of the DNA sequence.

Particularly preferred subject-matter of the invention are
 functionally equivalent DNA sequences which encode a PRPP
 30 amidotransferase gene and which show a sequence homology with the
 DNA sequence SEQ-ID No. 1 or SEQ-ID No. 3 of 80 to 100%, based on
 the total length of the DNA sequence.

Functionally equivalent sequences which encode a PRPP
 35 amidotransferase gene are in accordance with the invention those
 sequences which retain the desired functions, despite a deviating
 nucleotide sequence. Functional equivalents thus encompass
 naturally occurring variants of the sequences described herein,
 but also artificial nucleotide sequences, for example those which
 40 have been obtained by chemical synthesis and which are adapted to
 suit the codon usage of a plant.

A functional equivalent is also to be understood as meaning in
 particular natural or artificial mutations of an originally
 45 isolated sequence which encodes a PRPP amidotransferase and which
 continues to show the desired function. Mutations encompass
 substitutions, additions, deletions, exchanges or insertions of

In addition, the expression cassette according to the invention can also be employed for the transformation of bacteria, cyanobacteria, yeasts, filamentous fungi and algae, with the purpose of producing sufficient amounts of the enzyme PRPP amidotransferase.

Subject-matter of the invention are also plant proteins with PRPP
amidotransferase activity with an amino acid sequence homology to
25 the tobacco PRPP amidotransferase with the SEQ-ID NO: 2 or SEQ-ID
NO. 4 of 20 - 100% identity.

Particularly preferred are plant proteins with PRPP
amidotransferase activity with an amino acid sequence homology to
35 the tobacco PRPP amidotransferases with the sequences SEQ-ID
NO: 2 or SEQ-ID NO. 4 of 80 - 100% identity.

Overexpression, in a plant, of the gene sequence SEQ-ID NO. 1 or SEQ-ID NO. 3, which encodes a PRPP amidotransferase, results in an increased resistance to PRPP amidotransferase inhibitors. The transgenic plants generated thus are also subject-matter of the invention.

0050/50796

9

Expressional efficacy of the recombinantly expressed PRPP
amidotransferase gene can be determined, for example, in vitro by
shoot-meristem propagation or by a germination test. Moreover,
the expression of a PRPP amidotransferase gene which has been
5 altered in terms of type and level, and its effects on the
resistance to PRPP amidotransferase inhibitors can be tested in
greenhouse experiments using test plants.

Subject-matter of the invention are also transgenic plants,
10 transformed with an expression cassette according to the
invention containing the DNA sequence SEQ-ID No. 1 or SEQ-ID No.
3, which have been made tolerant to PRPP amidotransferase
inhibitors by additionally expressing the DNA sequence SEQ-ID No.
1 or SEQ-ID No. 3, and transgenic cells, tissues, parts and
15 propagation material of such plants. Especially preferred in this
context are transgenic crop plants such as, for example, barley,
wheat, rye, maize, soya, rice, cotton, sugar beet, canola,
sunflowers, flax, hemp, potatoes, tobacco, tomatoes, oilseed
rape, alfalfa, lettuce and the various tree, nut and grapevine
20 species, and also legumes.

A change in the nucleotide content in plants may be useful under
various circumstances. For example, nucleotides are added to
plant-based baby formulas to achieve a nutrient composition which
25 corresponds to breast milk. Furthermore, an optimized nucleotide
content would be helpful when patients are fed by gastric tube. A
reduced purine nucleotide content in nutritional plants is
relevant for the dietetic diet of patients suffering from gout.
Furthermore, nucleotides make and enhance flavors, so that an
30 altered nucleotide content has an effect on the palatability of
plants.

Another subject-matter of the invention are thus plants which,
following expression of the DNA sequence SEQ-ID No. 1 or SEQ-ID
35 No. 3 in the plant, have a modified purine nucleotide content. It
is preferred to increase the content of the purine nucleotides
IMP, AMP and/or GMP, or of their di- or trinucleotides ADP, ATP
or GDP and GTP.

40 A plant with a modified purine nucleotide content is generated,
for example, by expressing, in the plant, an additional DNA
sequence SEQ-ID No. 1 or SEQ-ID No. 3 in sense or antisense
orientation. A modified purine nucleotide content means that both
plants with an increased purine nucleotide content (in the case
45 of sense orientation) and plants with a reduced guanosine
nucleotide content (in the case of sense orientation

An increased purine nucleotide content means for the purposes of the present invention for example the artificially acquired ability of an increased purine nucleotide biosynthesis rate by functionally overexpressing the PRPP amidotransferase gene in the plant in comparison with the non-recombinant plant for the duration of at least one plant generation.

Another subject-matter of the invention is the use of plant PRPP amidotransferase for altering the methylxanthine concentration in plants.

Particularly preferred are sequences which ensure targeting into the apoplast, into plastids, into the vacuole, into the mitochondrion, into the endoplasmatic reticulum (ER), or which, owing to the absence of suitable operative sequences, ensure that the product remains in the compartment where it is formed, in the cytosol, (Kermode, Crit. Rev. Plant Sci. 15, 4 (1996), 285-423).

For example, the plant expression cassette can be introduced into the plant transformation vector pBinAR, see Example 5.

A suitable promoter of the expression cassette according to the invention is, in principle, any promoter which is capable of governing the expression of foreign genes in plants. It is preferred to use, in particular, a plant promoter or a promoter derived from a plant virus. Particularly preferred is the cauliflower mosaic virus CaMV 35S promoter (Franck et al., Cell 21(1980), 285-294). This promoter contains different recognition sequences for transcriptional effectors which, in their totality, lead to permanent and constitutive expression of the gene which has been introduced (Benfey et al., EMBO J., 8 (1989), 2195-2202).

The expression cassette according to the invention may also comprise a chemically inducible promoter which allows expression of the exogenous PRPP amidotransferase gene in the plant to be governed at a particular point in time. Such promoters which are described in the literature and which can be used are, inter alia, for example the PRP1 promoter (Ward et al., Plant. Mol. Biol. (1993) 22, 361-366), a salicylic acid-inducible promoter (WO 95/19443), a benzenesulfonamide-inducible promoter (EP 388186), a tetracyclin-inducible promoter (Gatz et al., Plant J. (1992) 2, 397-404), an abscisic acid-inducible promoter (EP0335528) or an ethanol- or cyclohexanone-inducible promoter

0050/50796

11

(WO 93/21334).

Particularly preferred promoters are furthermore those which ensure expression in tissues or parts of the plant in which the biosynthesis of purines or their precursors takes place. Promoters which ensure leaf-specific expression must be mentioned in particular. Promoters which must be mentioned are the potato cytosolic FBPase or the potato ST-LSI promoter (Stockhaus et al., EMBO J., 8 (1989) 2445-245).

10

A foreign protein can be expressed stably in the seeds of transgenic tobacco plants to an extent of 0.67% of the total soluble seed protein with the aid of a seed-specific promoter (Fiedler and Conrad, Bio/Technology 10 (1995), 1090-1094). The expression cassette according to the invention can therefore contain, for example, a seed-specific promoter (preferably the phaseolin promoter, the USP promoter or the LEB4 promoter), the LEB4 signal peptide, the gene to be expressed and an ER retention signal.

20

The inserted nucleotide sequence encoding a PRPP amidotransferase can be produced synthetically or obtained naturally or contain a mixture of synthetic and natural DNA components. In general, synthetic nucleotide sequences are generated with codons which are preferred by plants. These codons which are preferred by plants can be determined from codons with the highest protein frequency expressed in the plant species of the highest interest. When preparing an expression cassette, a variety of DNA fragments may be manipulated in order to obtain a nucleotide sequence which expediently reads in the correct direction and which is equipped with a correct reading frame. Adaptors or linkers can be added to the fragments in order to link the DNA fragments to each other.

Other suitable DNA sequences are artificial DNA sequences as long as they mediate the desired property by increasing the purine nucleotide content in the plant by overexpressing the PRPP amidotransferase gene in crop plants, as described above by way of example. Such artificial DNA sequences can be determined for example by backtranslating of proteins which have PRPP amidotransferase activity and which have been constructed by means of molecular modeling, or they can be determined by in vitro selection. Especially suitable are encoding DNA sequences which have been obtained by backtranslating a polypeptide sequence in accordance with the host-plant-specific codon usage. The specific codon usage can be determined readily by a skilled worker familiar with methods of plant genetics by means of

12

computer evaluations of other, known genes of the plant to be transformed.

Other suitable equivalent nucleic acid sequences according to the invention which must be mentioned are sequences which encode fusion proteins, the component of the fusion protein being a plant PRPP amidotransferase polypeptide or a functionally equivalent part thereof. The second part of the fusion protein can be, for example, another polypeptide with enzymatic activity or an antigenic polypeptide sequence, with the aid of which detection of PRPP amidotransferase expression is possible (for example myc-tag or his-tag). However, it is preferably a regulatory protein sequence such as, for example, a signal or transit peptide, which leads the PRPP amidotransferase protein to the desired site of action.

The promoter and terminator regions according to the invention should expediently be provided, in the direction of transcription, with a linker or polylinker containing one or more restriction sites for insertion of this sequence. As a rule, the linker has 1 to 10, in most cases 1 to 8, preferably 2 to 6, restriction sites. In general, the linker within the regulatory regions has a size less than 100 bp, frequently less than 60 bp, but at least 5 bp. The promoter according to the invention may be native, or homologous, or else foreign, or heterologous, to the host plant. The expression cassette according to the invention comprises, in the 5'-3' direction of transcription, the promoter according to the invention, any sequence and a region for transcriptional termination. Various termination regions can be exchanged for each other as desired.

Manipulations which provide suitable restriction cleavage sites or which eliminate the excess DNA or restriction cleavage sites may also be employed. *In vitro* mutagenesis, primer repair, restriction or ligation may be used in cases where insertions, deletions or substitutions such as, for example, transitions and transversions, are suitable. Complementary ends of the fragments may be provided for ligation in the case of suitable manipulations such as, for example, restriction, chewing-back or filling overhangs for blunt ends.

Preferred polyadenylation signals are plant polyadenylation signals, preferably those which correspond essentially to *Agrobacterium tumefaciens* T-DNA polyadenylation signals, in particular those of the gene 3 of the T-DNA (octopine synthase) of the Ti plasmid pTiACH5 (Gielen et al., EMBO J., 3 (1984),

0050/50796

14

In addition, constitutive expression of the exogenous PRPP amidotransferase gene is advantageous. On the other hand, inducible expression may also be desirable.

- 5 Using the recombination and cloning techniques cited above, the expression cassettes according to the invention can be cloned into suitable vectors which allow them to be multiplied, for example in *E. coli*. Suitable cloning vectors are, inter alia, pBR332, pUC series, M13mp series and pACYC184. Especially
10 suitable are binary vectors which are capable of replication both in *E. coli* and in agrobacteria.

- Another subject-matter of the invention relates to the use of an expression cassette according to the invention for transforming
15 plants, plant cells, plant tissues or parts of plants. The preferred purpose of the use is to increase the PRPP amidotransferase content in the plant.

- Depending on the choice of the promoter, expression may take
20 place specifically in the leaves, in the seeds or in other parts of the plant. Such transgenic plants and their propagation material and their plant cells, tissue or parts are another subject of the present invention.

- 25 The invention will now be illustrated by the examples which follow, without being limited thereto.

Examples

- 30 Recombinant methods on which the use examples are based:

General cloning methods

- Cloning methods such as restriction cleavages, agarose gel
35 electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linking DNA fragments, transformation of *Escherichia coli* cells, growing bacteria and the sequence analysis of recombinant DNA were carried out as described by Sambrook et al. (1989) (Cold Spring
40 Harbor Laboratory Press: ISBN 0-87969-309-6).

Sequence analysis of recombinant DNA

- Recombinant DNA molecules were sequenced using an ABI laser
45 fluorescence DNA sequencer, following the method of Sanger (Sanger et al., Proc. Natl. Acad. Sci. USA, 74(1977), 5463-5467). Fragments resulting from a polymerase chain reaction were

15

Analysis of total RNA from plant tissues

5

Total RNA from plant tissues was isolated as described by Logemann et al. (Anal. Biochem. 163(1987), 21). For the analysis, in each case 20 µg of RNA were separated in a formaldehyde-containing 1.5% agarose gel and transferred to nylon membranes (Hybond, Amersham). Specific transcripts were detected as described by Amasino (Anal. Biochem. 152(1986), 304). The DNA fragments employed as probe were radiolabeled with a Random Primed DNA Labeling Kit (Roche, Mannheim) and hybridized by standard methods (see Hybond instructions, Amersham).

Hybridization signals were visualized by autoradiography with the aid of Kodak X-OMAT AR films.

Unless otherwise specified, the chemicals used were analytical grade and obtained from Fluka (Neu-Ulm), Merck (Darmstadt), Roth (Karlsruhe), Serva (Heidelberg) and Sigma (Deisenhofen). Solutions were made with a refined, pyrogen-free water, termed H₂O hereinbelow, from a Milli-Q water refining system (Millipore, Eschborn). Restriction endonucleases, DNA-modifying enzymes and molecular biologic kits were obtained from AGS (Heidelberg), Amersham (Braunschweig), Biometra (Göttingen), Roche (Mannheim), Genomed (Bad Oeynhausen), New England Biolabs (Schwalbach/Taunus), Novagen (Madison, Wisconsin, USA), Perkin-Elmer (Weiterstadt), Pharmacia (Freiburg), Qiagen (Hilden) and Stratagene (Heidelberg). Unless otherwise specified, they were used in accordance with the manufacturer's instructions.

The bacterial strains used hereinbelow (*E. coli*, XL-1 Blue) were obtained from Stratagene. *E. coli* AT 2465 was obtained from the *coli* genetic stock center (Yale University, New Haven). The agrobacterial strain used for transforming plants (*Agrobacterium tumefaciens*, C58C1 with plasmid pGV2260 or pGV3850kan) was described by Deblaere et al. (Nucl. Acids Res. 13 (1985), 4777). Alternatively, it is also possible to use the agrobacterial strain LBA4404 (Clontech) or other suitable strains. Vectors which can be used for cloning are pUC19 (Yanish-Perron, Gene 33(1985), 103-119), pBluescript SK- (Stratagene), pGEM-T (Promega), pZero (Invitrogen), pBin19 (Bevan et al., Nucl. Acids Res. 12(1984), 8711-8720) and pBinAR (Höfgen and Willmitzer, Plant Science 66 (1990), 221-230).

5

Q

—

The resulting 1.9 kb fragment was used for a heterologous screening of a *Nicotiana tabacum* var. SR-1 (Stratagene) cDNA library. 3.0×10^5 lambda phages of the cDNA library were plated onto agar plates with *E. coli* XL1-blue as bacterial strain. The phage DNA was transferred to nitrocellulose filters (Gelman Sciences) by means of standard methods (Sambrook et al. (1989), Cold Spring Harbor Laboratory Press ISBN 0-87969-309-6) and fixed on the filters. The hybridization probe used was the above-described PCR fragment, which was radiolabelled with the aid of the "Multiprime DNA labeling systems" (Amersham Buchler) in the presence of α - ^{32}P -dCTP (specific activity 3000 Ci/mmol) following the manufacturer's instructions. The membranes were hybridized after prehybridization at 60°C in 3 x SSPE, 0.1% sodium dodecyl sulfate (w/v), 0.02% polyvinylpyrrolidone (w/v), 0.02% Ficoll 400 (w/v) and 50 mg/ml calf thymus DNA for approx. 12 hours. The filters were subsequently washed for 60 minutes in 2 x SSPE, 0.1% sodium dodecyl sulfate (w/v) at 60°C. Positively hybridizing phages were visualized by autoradiography and singled out by means of standard techniques (Sambrook et al. (1989); Cold Spring Harbor Laboratory Press: ISBN 0-87969-309-6) and transferred into plasmid (Stratagene).

17

Following restriction and sequence analysis, two different clones were identified, Ntpur1.1 (clone 7.2) containing the DNA sequence SEQ-ID No. 1 and Ntpur1.2 (clone 9.2) containing the DNA sequence SEQ-ID No. 3, which encode reading frames with homology to *Arabidopsis thaliana* AtATase1. The amino acid sequences of Ntpur1.1 (SEQ-ID No. 2 - length: 573 amino acids) and Ntpur1.2 (SEQ-ID No. 4 - length: 573 amino acids) show 97% identity, see Table 1. The homology with AtATase1 at amino acid level is 81% in the case of Ntpur1.1 and 85% in the case of Ntpur1.2. The continuous reading frames start with nucleotide base 49 (Ntpur1.1) and 25 (Ntpur1.2) respectively, and are translated into polypeptides 573 amino acids in length.

Table 1

15 Amino acid comparison Ntpur1.1 x Ntpur1.2:

	1	MAATVSTASAAATNKSPLSQPLDKPFCSPSQKLLSLSPKTLPKPYRTLVT	50
	1	MAATVSTASAAATNKYPLSQPLDKPFCSLSQKLLSLSPKTHPKPYRTLIT	50
20	51	ASSKNPLNDVVSFKKSADNTLDSYFDDDDKPREECGVVGIYGDSEASRLC	100
	51	ASSKNPLNDVISFKKSADNTLDSYFDDDDKPREECGVVGIYGDSEASRLC	100
	101	YLALHALLHRGQEGAGIVAVNDDVLKSITGVGLVSDVFNESKLDQLPGDM	150
25	101	YLALHALQHRGQEGAGIVAVNDDVLKSITGVGLVSDVFNESKLDQLPGDM	150
	151	AIGHVWYSTAGSSMLKNVQPFVANYKFGSVGVAHNGNLVNYKLLRGELEE	200
	151	AIGHVRYSTAGSSMLKNVQPFVASYKFGSVGVAHNGNLVNYKLLRSELEE	200
30	201	NGSIFNTSSDTEVVLHLIAISKARPFLLRIVEACEKIEGAYSMVFVTEDEK	250
	201	NGSIFNTSSDTEVVLHLIAISKARPFLLRIVEACEKIEGAYSMVFVTEDEK	250
	251	LVAVRDPHGFRPLVMGRRSNGAVVFASSETCALDLIEATYEREVNPGEVVV	300
	251	LVAVRDPHGFRPLVMGRRSNGAVVFASSETCALDLIEATYEREVNPGEVVV	300
35	301	VDKDGVHSIYLMPPHPEHKSCIFEHIYFALPNSVVFGRSVYESRRAFGEIL	350
	301	VDKDGVQSICLMPHPERKSCIFEHIYFALPNSVVFGRSVYESRRAFGEIL	350
	351	ATEAPVECDVGIAVPDPSGIVAALGYAAKAGVPFQQGLIRSHYVGRTFIEP	400
40	351	ATEAPVECDVVIAPDPSGIVAALGYAAKAGVPFQQGLIRSHYVGRTFIEP	400
	401	SQKIRDFGVKLKLSFVRALLEGKRVVVDDSIVRGTTSSKIVRLLKEAGA	450
	401	SQKIRDFGVKLKLSFVRALLEGKRVVVDDSIVRGTTSSKIVRLLKEAGA	450
45	451	KEVHMRIASPPPIIASCYYGVDTPSSDELISNRMSVEEIKEFIGSDSLAFL	500
	451	KEVHMRIASPPPIIASCYYGVDTPSSDELISNRMSVEEIKEFIGSDSLAFL	500

0050/50796

18

501 PMDSLNLKLLGNDKSFYACFSGNYPVEPTGKVKRIGDFMDDGLSGDMDS 550

|||||

501 PMDSLNLKLLGNDKSFYACFSGNYPVEPTGKVKRIGDFMDDGLSGDMDS 550

551 IDGGWLPGSSRVQKILNEVRTG 573

|||||

551 IDGGWLPGSSRVQKILNEVRTS 573

5

Compared with bacterial and human PRPP amidotransferase sequences, the plant proteins (Ntpur1.1, Ntpur1.2, AtATase1) show an extended N-terminus with a large proportion of basic amino acids (Table 2), which suggests the function of a transit peptide for plastid import (von Heijne et al., Eur. J. Biochem. 180(1989), 535-545).

Table 2

Sequence comparison of Arabidopsis thaliana (AtATase1), Bacillus subtilis (BacSu_purF), Human (pur1_hum) and Nicotiana tabacum (Ntpur1.1), Ntpur1.2) PRPP amidotransferase proteins.

		1				50
20	AtATase1	~~~~~	~~~~~	~~~~~SLN	QTILLTPINL	SLSSPNPSLN
	BacSu_purF	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	Ntpur1	LAPHLLFLLS	SFFPPPMAAT	VSTASAAATN	KSPLSQPLDK	PFCSPSQKL.
	Ntpur1-2	~~~~~LS	SFFPPPMAAT	VSTASAAATN	KYPLSQPLDK	PFCSLSQKL.
	pur1_hum	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
		51				100
25	AtATase1	LHISLS.FLL	PSPLLLLHSS	MESPPTSPLL	HHPKNNSHAP	FDYHNDEDDE
	BacSu_purF	~~~~~	~~~~~	~~~~~	~~~~~MLAEIK	~~~~~
	Ntpur1	..LSLSPKTL	PKPYRTLVT	SSKNPLNDVV	SFKKSADNTL	DSYFDDDD..
	Ntpur1-2	..LSLSPKTH	PKPYRTLIT	SSKNPLNDVI	SFKKSADNTL	DSYFDDDD..
	pur1_hum	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~MELEEL
		101				150
30	AtATase1	KPREECGVVG	IYGDPE....	..ASRLFYLA	LHALQHRGQE	GAGIVTVSPE
	BacSu_purF	GLNEECGVFG	IWGHEE....	..APQITYYG	LHSLQHRGQE	GAGIVATDGE
	Ntpur1	KPREECGVVG	IYGDSE....	..ASRLCYLA	LHALLHRGQE	GAGIVAVN.D
	Ntpur1-2	KPREECGVVG	IYGDSE....	..ASRLCYLA	LHALQHRGQE	GAGIVAVN.D
	pur1_hum	GIREECGVFG	CIASGEWPTQ	LDVPHVITLG	LVGLQHRGQE	SAGIVTSDGS
35		151				200
	AtATase1	KV..LQTITG	VGLVSEVFNE	SKLDQL.PGE	FAIAHVRYST	AGASMLKNVQ
	BacSu_purF	K...LTAHKG	QGLITEVFQN	GELSKV.KGK	GAIGHVRYAT	AGGGGYENVQ
	Ntpur1	DV..LKSITG	VGLVSDVFNE	SKLDQL.PGD	MAIGHVWYST	AGSSMLKNVQ
	Ntpur1-2	DV..LKSITG	VGLVSDVFNE	SKLDQL.PGD	MAIGHVRYST	AGSSMLKNVQ
40	pur1_hum	SVPTFKSHKG	MGLVNHVFTE	DNLKKLYVSN	LGIGHTRYAT	TGKCELENCQ
		201				250
	AtATase1	PFV.AGYRFG	SIGVAHNGNL	VNYKTLRAML	EENGSIFFNTS	SDTEVVLHLI
	BacSu_purF	PLLFRSQNNG	SLALAHNGNL	VNATQLKQQL	ENQGSIFQTS	SDTEVLAHLI
	Ntpur1	PFV.ANYKFG	SVGVAHNGNL	VNYKLLRGEL	EENGSIFFNTS	SDTEVVLHLI
	Ntpur1-2	PFV.ASYKFG	SVGVAHNGNL	VNYKLLRSEL	EENGSIFFNTS	SDTEVVLHLI
45	pur1_hum	PFVVETLH.G	KIAVAHNGEL	VNAARLRKKL	LRHGIGLSTS	SDSEMITQLL
		251				300
	AtATase1	AISKAR....	..PFFMRIID	ACEKLQGAYS	MVFVTEKLV	AVRDPYGFRR

0050/50796

19

	BacSu_purF	KRSGHF....	..TLKDQIKN	SLSMLKGAYA	FLIMTETEMI	VALDPNGLRP
	Ntpur1	AISKAR....	..PFLLRIVE	ACEKIEGAYS	MVFVTEDEKL	AVRDPHGFRP
	Ntpur1-2	AISKAR....	..PFLLRIVE	ACEKIEGAYS	MVFVTEDEKL	AVRDPHGFRP
	pur1_hum	AYTPPQEQDD	TPDWVARIKN	LMKEAPTAYS	LLIMHRDVIY	AVRDPYGNRP
		301				350
5	AtATasel	LVMGR.....R	SNGAVVFASE	TCALDLIEAT	YEREVYPGEV
	BacSu_purF	LSIGM.....M	GD.AYVVASE	TCAFDVVGAT	YLREVEPGEM
	Ntpur1	LVMGR.....R	SNGAVVFASE	TCALDLIEAT	YEREVNPGEV
	Ntpur1-2	LVMGR.....R	SNGAVVFASE	TCALDLIEAT	YEREVNPGEV
	pur1_hum	LCIGRLIPVS	DINDKEKSTS	ETEGWVVSSE	SCSFLSIGAR	YYREVLPGEI
		351				400
10	AtATasel	LVVDKDGVS	QCLMPKFEPK	Q...CIFEHI	YFSLPNSIVF	GRSVYESRHV
	BacSu_purF	LIINDEGMKS	ERFSMNINRS	I...CSMEYI	YFSRPDSNID	GINVHSARKN
	Ntpur1	VVVDKDGVS	IYLMPPHEHK	S...CIFEHI	YFALPNSVVF	GRSVYESRRA
	Ntpur1-2	VVVDKDGVS	ICLMPHPERK	S...CIFEHI	YFALPNSVVF	GRSVYESRRA
	pur1_hum	VEISRHNVT	LDIISRSEGN	PVAFCIFEYV	YFARPDMSFE	DQMVTVRVYR
		401				450
15	AtATasel	FGEILATESP	VECDVVIAPV	DSGVVAALGY	AAKSGVPFQQ	GLIRSHYVGR
	BacSu_purF	LGMMLAQESA	VEADVVTGVP	DSSISAAIGY	AEATGIPYEL	GLIKNRYVGR
	Ntpur1	FGEILATEAP	VECDVGIAPV	DSGIVAALGY	AAKAGVPFQQ	GLIRSHYVGR
	Ntpur1-2	FGEILATEAP	VECDVVIAPV	DSGVVAALGY	AAKAGVPFQQ	GLIRSHYVGR
20	pur1_hum	CGQQLAIEAP	VDADLVSTVP	ESATPAALAY	AGKCGLPYVE	VLCKNRYVGR
		451				500
25	AtATasel	TFIEPSQKIR	DFGVKLKLS	VRGVLEGKRV	VVVDDSIVRG	TTSSKIVRLL
	BacSu_purF	TFIQPSQALR	EQGVRMKLSA	VRGVVEGKRV	VMVDDSIVRG	TTSSRIVTML
	Ntpur1	TFIEPSQKIR	DFGVKLKLS	VRALLEGKRV	VVVDDSIVRG	TTSSKIVRLL
	Ntpur1-2	TFIEPSQKIR	DFGVKLKLS	VRVLEGKRV	VVVDDSIVRG	TTSSKIVRLL
	pur1_hum	TFIQPNMRLR	QLGVAKKFGV	LSDNFKGKRI	VLVDDSIVRG	NTISPIIKLL
		501				550
30	AtATasel	REAGAKEVHM	RIASPPIVAS	CYYGVDTPSS	EELISNRLSV	EEINEFIGSD
	BacSu_purF	REAGATEVHV	KISSPPIAHP	CFYGIDTSTH	EELIASSHSV	GEIRQEIGAD
	Ntpur1	KEAGAKEVHM	RIASPPIIAS	CYYGVDTPSS	DELISNRMSV	EEIKEFIGSD
	Ntpur1-2	KEAGAKEVHM	RIASPPIIAS	CYYGVDTPSS	DELISNRMSV	EEIKEFIGSD
	pur1_hum	KESGAKEVHI	RVASPPIKYP	CFMGINIPTK	EELIANKPEF	DHLAEYLGAN
		551				600
35	AtATasel	SLAFLSFDTL	KKHL.....GK...	.DSK.SFCYA	
	BacSu_purF	TLSFLSVEGL	LKGI.....GRKYD	.DSNCGQCLA	
	Ntpur1	SLAFLPMDSL	NKLL.....GN...	.DSK.SFCYA	
	Ntpur1-2	SLAFLPMDSL	NKLL.....GN...	.DSK.SFCYA	
	pur1_hum	SVVYLSVEGL	VSSVQEGIKF	KKQKEKKHDI	MIQENGNGLE	CFEKSGHCTA
		601				650
40	AtATasel	CFTGDYPVKP	TEVKVKRGGG	DFIDDGLVGS	FENIEAGWVR	~~~~~
	BacSu_purF	CFTGKYPTI	YQDVTLPVK	EAVLTK~~~~	~~~~~	~~~~~
	Ntpur1	CFSGNYPVEP	TG.KVKR.IG	DFMDDGLSGD	MDSIDGGWLP	GSSRVQKTIL
	Ntpur1-2	CFSGNYPVEP	TG.KVKR.IG	DFMDDGLSGD	MDSIDGGWLP	GSSRVQKTIL
	pur1_hum	CLTGKYPVEL	EW~~~~~	~~~~~	~~~~~	~~~~~
		651				
45	AtATasel	~~~~~				
	BacSu_purF	~~~~~				
	Ntpur1	NEVRTG				
	Ntpur1-2	NEVRTS				
	pur1_hum	~~~~~				

0050/50796

20

Example 2

Expression of tobacco PRPP amidotransferase in E. coli

- 5 The purpose of expressing Ntpur1.2 in E. coli was to prove that the Ntpur1.2-encoded PRPP amidotransferase enzyme was active. To this end, a 1523 bp fragment was amplified in a PCR with Pfu polymerase using the oligonucleotides Jle336:
5'-ttttgctagcgcactcgtattttgacg-3' and Jle337:
5'-aaaaagatctcaggttctaacttcat -3' and Ntpur1.2 DNA as template.
- 10 The DNA fragment generated encodes a PRPP amidotransferase enzyme with is truncated N-terminally by 86 amino acids and no longer contains the transit peptide to be received. This truncated form of PRPP amidotransferase enzyme starts N-terminally with the
- 15 amino acids MDSYFDDDD. Using the oligonucleotides, an NheI cleavage site and a BglII cleavage site were inserted via which the fragment generated was ligated into the NheI- and BamHI-cleaved expression vector pET11a (Novagen).
- 20 For expression, the E. coli strain BL21(DE3)LysS (Novagen) was transformed with the construct pETNtpur1.2 which had thus been generated. Following overnight culture, a day culture was inoculated to OD₆₀₀ = 0.1 and, after an OD₆₀₀ = 0.7 had been reached, induced with 1mM IPTG. A total cell extract was produced
- 25 by the pressure disruption method ("French press") in 50mM Tris-HCl, pH 7.4; 150mM NaCl. Following SDS polyacrylamide gel electrophoresis, an overexpressed protein of approx. 65 kDa was excised from the gel. To produce antisera, the protein was injected into rabbits (contractor: Eurogentec, Herstal, Belgium).

30

Example 3

Assay system for measuring the activity of plant PRPP amidotransferase activity

35

- The above-described method for measuring plant PRPP amidotransferase activity by the method of Reynolds et al. (Archives of Biochemistry and Biophysics 229 (1984), 623-631) is not suitable for high-throughput assaying owing to the use of
- 40 radioactive materials. This is why an alternative assay system with which the plant PRPP amidotransferase activity is detected in the protein extract is detected on the basis of the formation of the reaction product glutamate, based on the method described by Shid and Ishii (Journal of Biological Chemistry 66 (1969),
- 45 175-181) for E. coli PRPP amidotransferase. The concentration of

0050/50796

21

the glutamate which forms is measured by converting it with glutamate dehydrogenase (GluDH) and monitoring APADH formation photometrically at 363 nm.



10 (PRPP = phosphoribosyl pyrophosphate, PRA = phosphoribosylamine, APAD = 3-acetylpyridineadenin dinucleotide, PRAT = PRPP amidotransferase)

To this end, the reaction batch (see below) is incubated at 37°C
15 for up to 60 minutes and the reaction was quenched by incubation at 95°C for 5 minutes.

Reaction batch:

20	375 μl	100 mM	Tris/HCl buffer pH 8.0
	75 μl	100 mM	MgCl ₂
	75 μl	30 mM	phosphoribosyl pyrophosphate
	75 μl	100 mM	L-glutamine
	50 μl		H ₂ O
25	<u>100 μl</u>		protein extract
	750 μl		

The glutamate formed was detected in the detection batch (see below) by measuring the increase in APADH photometrically at
30 363 nm following addition of glutamate dehydrogenase.

Detection batch:

	375 μl	100 mM	Tris/HCl buffer pH 8.0
35	75 μl	500 mM	KCl
	125 μl		H ₂ O
	75 μl	3 mM	APAD
	<u>100 μl</u>		of the reaction batch
	750 μl		

40

Start of the detection reaction with 2 μl (approx. 4 units) glutamate dehydrogenase (Sigma).

The assay system lends itself in particular for measuring PRPP
45 amidotransferase activity from plant material and in expression extracts, for example from baculovirus-infected insect cells.

5

10 oligonucleotides 5'-tat agg atc cat gga ctc cta ttt tga cg-3' and 5'-atg aat tct agc tgg ttc taa ctt c-3', 200 μ M deoxynucleotides (Pharmacia), 0.04 U/ μ l Pfu polymerase (Stratagene) and buffer conditions were set following the manufacturer's instructions.

Step 1:

Step 2:

30

35 instructions for generating recombinant baculoviruses by means of Sf21 insect cells (Invitrogen). Sf21 insect cells were infected with the recombinant baculovirus (BvNtpurl.2). After 2-4 days, the cells were harvested by centrifugation. A protein of approx. 54kDa, which corresponds to the expected size of PRPP

40 amidotransferase, was identified in the total extract by SDS polyacrylamide gel electrophoresis. A total cell extract was prepared by the pressure disruption method ("French press") in extraction buffer (100 mM HEPES pH 8.0; 2.5 mM EDTA; 10% glycerol; 20 mM DTE; 0.2 mM PEFA block) and, after being freed
45 from salt over a PD10 column (Pharmacia), used for measuring PRPP amidotransferase activity in the assay described (see Example 3).

Example 5

Generation of plant transformation vectors

- 5 To generate binary vectors for plant transformation, clone Ntpur1.1 was cleaved with SmaI and EcoRV, and a fragment comprising 1482 bp was isolated and ligated into the SmaI-cleaved vector pBinAR (Höfgen and Willmitzer, Plant Science 66(1990), 221-230). The antisense and sense constructs thus obtained were
10 termed pBinAR-Ntpur1A and pBinAR-Ntpur1, respectively; see Figure 1.

Example 6

15 Generation of transgenic tobacco plants

- Plasmid pBinAR-Ntpur1A and pBinAR-Ntpur1 were transformed into Agrobacterium tumefaciens C58C1:pGV2260 (Deblaere et al., Nucl. Acids. Res. 13(1984), 4777-4788). To transform tobacco plants
20 (Nicotiana tabacum cv. Samsun NN), a 1:50 dilution of an overnight culture of a positively transformed agrobacterial colony in Murashige-Skoog medium (Murashige and Skoog, Physiol. Plant. 15(1962), 473) supplemented with 2% sucrose (2MS medium) was used. Leaf disks of sterile plants (in each case approx.
25 1 cm²) were incubated in a Petri dish for 5-10 minutes with a 1:50 agrobacterial dilution. This was followed by 2 days' incubation in the dark at 25°C on 2MS medium with 0.8% Bacto agar. Cultivation was continued after 2 days and at 16 hours light/8 hours dark and continued in a weekly rhythm on MS medium
30 with 500 mg/l claforan (cefotaxime-sodium), 50 mg/l kanamycin, 1 mg/l benzylaminopurine (BAP), 0.2 mg/l naphthylacetic acid and 1.6 g/l glucose. Growing shoots were transferred to MS medium supplemented with 2% sucrose, 250 mg/l claforan and 0.8% Bacto agar.
35
Regenerated shoots were obtained on 2MS medium with kanamycin and claforan, transferred into soil after rooting, and, after cultivation for two weeks in a controlled-environment cabinet in a 16-hour light/8-hour dark rhythm at 60% atmospheric humidity,
40 analyzed for PRPP amidotransferase expression and activity and for altered metabolite contents and phenotypic growth characteristics. Altered nucleotide contents can be determined for example following the method of von Stitt et al., FEBS Letters 145(1982), 217-222.

0050/50796

24

Example 7

Analysis of transgenic plants

5 Transgenic plants which were transformed with the construct with
 pBinAR-Ntpurl are characterized by a growth which is reduced by
 different degrees and by large-scale bleaching of the leaves in
 comparison with untransformed control plants (Fig. 2). RNA
 analysis by the Northern blot technique showed a reduced amount
 10 of Ntpurl.1-RNA in transgenic lines with the above-described
 phenotype (Fig. 3). These effects were also observed in
 subsequent generations of the transgenic lines.

To test the correlation with growth reduction, PRPP
 15 amidotransferase activity in the transgenic lines was measured
 and compared with that in untransformed controls. To this end, in
 each case approx. 30 g of leaves from plants approximately 20 cm
 in height were homogenized with 50 ml of extraction buffer at
 +4°C.

20

Extraction buffer:

100 mM	HEPES pH 8,0
2.5 mM	EDTA
25 10%	glycerol
20 mM	DTE
0,2 mM	PEFA block (40mM)

The disruption extract was filtered through Miracloth
 30 (Calbiochem, Bad Soden) and spun at 16,000 rpm in a Sorval
 centrifuge. The resulting supernatant was precipitated with
 ammonium sulfate at 4°C. The 30% - 60% fraction was solubilized in
 an extraction buffer and freed from salt by means of a PD-10
 column (Pharmacia, Sweden). The extract thus obtained is stable
 35 for at least 24 hours and can be stored over a prolonged period
 at -20°C after addition of glycerol (end concentration 50%). The
 extract can be employed directly in the activity determination.
 Compared to wild-type plants, the PRPP amidotransferase activity
 in the transgenic lines was markedly reduced, see Fig. 4. Fig. 4A
 40 shows the PRPP amidotransferase activity based on the protein
 quantity. Fig. 4B shows the PRPP amidotransferase activity based
 on the fresh weight.

0050/50796

25

These data establish a direct connection between reduced PRPP amidotransferase activity and reduced growth of the tobacco plants and thus identify PRPP amidotransferase for the first time as suitable target protein for herbicidal active ingredients.

5

Example 8

Search for PRPP amidotransferase activity inhibitors

- 10 The in-vitro assay described in Example 3 can be used together with high-throughput methods for searching for PRPP amidotransferase activity inhibitors. To this end, the PRPP amidotransferase activity can be prepared from plant tissue, see Example 7. Alternatively, a plant PRPP amidotransferase can be
- 15 expressed in *E. coli*, insect cells or in another suitable expression system. Known PRPP amidotransferase inhibitors such as glutamine antagonists were identified in this manner.

Example 9

20

Analysis of the adenine and guanine nucleotide contents in transgenic plants.

- Leaf material (in each case 5 disks of 6 mm diameter) was
- 25 harvested from wild-type plants and transgenic plants transformed with the construct pBinAR-Ntpurl and the subsequent generation (lines 3.1, 3.2, 3.9, 25.1 and 38.8) and frozen immediately in liquid nitrogen. TCA extracts were subsequently prepared by standard methods and employed for the determination of the
- 30 nucleotide contents.

In the transgenic plants, with the exception of line 38.8, AMP is reduced greatly in the green regions of the leaf and less in the yellow regions of the leaf compared to the wild type (WT) (see

35 Fig. 5).

No changes compared to the wild type were observed for the guanosine nucleotide GTP, GDP and GMP.

40

45

We claim:

1. A DNA sequence containing the encoding region of a plant PRPP
amidotransferase, wherein this DNA sequence has the
nucleotide sequence SEQ-ID No. 1 or SEQ-ID No. 3.
2. A DNA sequence hybridizing with the DNA sequence SEQ-ID No. 1
or SEQ-ID No. 3 as claimed in claim 1 or parts thereof or
derivatives, derived from this sequence by insertion,
deletion or substitution and encoding a protein which has the
biological activity of a PRPP amidotransferase.
3. A protein with PRPP amidotransferase activity comprising an
amino acid sequence which constitutes a subsequence of at
least 100 amino acids from SEQ-ID No. 2 or SEQ-ID No. 4.
4. A protein as claimed in claim 3, which comprises, as amino
acid sequence, the subsequence 100 - 450 from SEQ-ID No. 2 or
SEQ-ID No. 4.
5. A protein as claimed in claim 4, which comprises, as amino
acid sequence, the sequence shown in SEQ-ID No. 2 or SEQ-ID
No. 4.
6. The use of a DNA sequence as claimed in claim 1 or 2 for
introduction into pro- or eukaryotic cells, this sequence
optionally being linked to control elements which ensure
transcription and translation in the cells and leading to the
expression of a translatable mRNA which causes the synthesis
of a plant PRPP amidotransferase.
7. The use of a DNA sequence as claimed in claim 1 or 2 for
generating an assay system for identifying herbicidally
active plant PRPP amidotransferase inhibitors.
8. A method of finding herbicidally active substances which
inhibit the activity of the plant PRPP amidotransferase,
which comprises preparing, in a first step, PRPP
amidotransferase using a DNA sequence as claimed in claim 1
or 2 and measuring, in a second step, the activity of the
plant PRPP amidotransferase in the presence of a test
substance.
9. The method as claimed in claim 9, wherein the plant PRPP
amidotransferase is measured in a high-throughput screening
(HTS). The method as claimed in claim 9, wherein the plant

0050/50796

27

PRPP amidotransferase is measured in a high-throughput screening (HTS).

10. A method of identifying herbicidally active substances which inhibit the PRPP amidotransferase activity in plants, with the following steps:
- a) the generation of transgenic plants, plant tissues or plant cells which comprise an additional DNA sequence encoding an enzyme with PRPP amidotransferase activity and which are capable of overexpressing an enzymatically active PRPP amidotransferase;
 - b) applying a substance to transgenic plants, plant cells, plant tissue or plant parts and to untransformed plants, plant cells, plant tissue or plant parts;
 - c) determining the growth or the viability of the transgenic and the untransformed plants, plant cells, plant tissue or plant parts after application of the chemical substance; and
 - d) comparing the growth or the viability of the transgenic and the untransformed plants, plant cells, plant tissue or plant parts after applying the chemical substance;
- where a suppression of the growth or the viability of the untransformed plants, plant cells, plant tissue or plant parts, but an absence of potent suppression of the growth or viability of the transgenic plants, plant cells, plant tissue or plant parts, confirms that the substance of b) shows herbicidal activity and inhibits the PRPP amidotransferase enzyme activity in plants.
11. An assay system based on the expression of a DNA sequence SEQ-ID No. 1 or SEQ-ID No.9 as claimed in claim 1 or 2 for identifying herbicidally active plant PRPP amidotransferase inhibitors.
12. An assay system as claimed in claim 11 for identifying herbicidally active plant PRPP amidotransferase inhibitors, which comprises incubating the enzyme with a test substrate to be studied and, after a suitable reaction time, determining the enzymatic activity of the enzyme in comparison with the activity of the uninhibited enzyme.

13. A plant PRPP amidotransferase inhibitor.

5

16. A method of eliminating undesired vegetation, which comprises treating the plants to be eliminated with a compound which binds specifically to PRPP amidotransferase encoded by a DNA sequence as claimed in claim 1 or 2 and which inhibits its function.

10

20

25

30

35

40

45

0050/50796

28

PRPP amidotransferase

Abstract

5

The present invention relates to DNA sequences encoding a polypeptide with PRPP amidotransferase (EC 2.4.2.14) activity. The invention furthermore relates to the use of these nucleic acids for generating a test system.

10

15

20

25

30

35

40

45




Fig. 2

2/4




Fig. 3




Fig. 4

3/4





Fig. 5



Declaration, Power of Attorney and Petition

Page 1 of 3

0050/050796

Customer No.

We (I), the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PLANT PRPP AMIDOTRANSFERASE

the specification of which

☐ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____.

☒ was filed as PCT international application

Number PCT/EP/00/09839 _____

on 07 October 2000 _____,

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
19949000.7	Germany	11 October 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

0050/050796

We (I) hereby claim the benefit under Title 35, United States Codes, § 119(c) of any United States provisional application(s) listed below.

(Application Number)_____
(Filing Date)_____
(Application Number)_____
(Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.**Filing Date****Status (pending, patented,
abandoned)**

_____	_____	_____
_____	_____	_____
_____	_____	_____

And we (I) hereby appoint Nixon & Vanderhye P.C., Attorneys at Law, 1100 North Glebe Road, Arlington, Virginia 22201-4714, our attorneys, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to sign the drawings, to receive the patent, and to transact all business in the Patent Office connected therewith.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Declaration

Page 3 of 3

0050/050796

1-00 Jens Lerchl
NAME OF INVENTOR

Jens Lerchl
Signature of Inventor

Date October 26, 2000

Im Steg 36
68526 Ladenburg
Germany
Citizen of: Germany DEX
Post Office Address: same as residence

2-00 Thomas Ehrhardt
NAME OF INVENTOR

Thomas Ehrhardt
Signature of Inventor

Date October 26, 2000

Maulbronner Hof 49
67346 Speyer
Germany
Citizen of: Germany DEX
Post Office Address: same as residence

3-00 Uwe Sonnewald
NAME OF INVENTOR

Uwe Sonnewald
Signature of Inventor

Date October 26, 2000

Am Hange 6
06484 Quedlinburg
Germany
Citizen of: Germany DEX
Post Office Address: same as residence

4-00 Ralf Boldt
NAME OF INVENTOR

Ralf Boldt
Signature of Inventor

Date October 26, 2000

Stieg 19
06484 Quedlinburg
Germany
Citizen of: Germany DEX
Post Office Address: same as residence

0050/50796

SEQUENCE LISTING

<110> BASF Aktiengesellschaft

<120> Plant PRPP amidotransferase

<130> NAE991125

<140>

<141>

<160> 4

<170> PatentIn Vers. 2.0

<210> 1

<211> 1879

<212> DNA

<213> Nicotiana tabacum

<220>

<221> CDS

<222> (49)..(1767)

<400> 1

ctagccccc acttgctttt ccttctgtcc tccttttttc caccgccc atg gcc gcc 57
Met Ala Ala
1

acc gtc tcc acc gcc tct gcc gcc gcc acc aat aaa tct cct ctt tcg 105
Thr Val Ser Thr Ala Ser Ala Ala Thr Asn Lys Ser Pro Leu Ser
5 10 15

cag ccc ctc gac aaa ccc ttt tgc tcc cca tct caa aag ctc tta tct 153
Gln Pro Leu Asp Lys Pro Phe Cys Ser Pro Ser Gln Lys Leu Leu Ser
20 25 30 35

tta tcc cct aaa acc ctc cca aaa ccc tat aga act ctc gtc acc gca 201
Leu Ser Pro Lys Thr Leu Pro Lys Pro Tyr Arg Thr Leu Val Thr Ala
40 45 50

tct tcc aaa aac ccc tta aac gac gtc gtt tcg ttt aag aaa tca gct 249
Ser Ser Lys Asn Pro Leu Asn Asp Val Val Ser Phe Lys Lys Ser Ala
55 60 65

gac aat aca ttg gac tcg tat ttt gac gat gaa gac aaa ccc cgt gaa 297
Asp Asn Thr Leu Asp Ser Tyr Phe Asp Asp Glu Asp Lys Pro Arg Glu
70 75 80

0050/50796

2

gag tgt ggc gtt gtg ggc atc tat ggc gac tca gaa gct tca cgc ctt	345
Glu Cys Gly Val Val Gly Ile Tyr Gly Asp Ser Glu Ala Ser Arg Leu	
85 90 95	
tgc tat tta gca ctt cac gcg ctt cta cac cgt ggc caa gaa ggc gcc	393
Cys Tyr Leu Ala Leu His Ala Leu Leu His Arg Gly Gln Glu Gly Ala	
100 105 110 115	
ggc att gtc gcc gtt aac gac gac gtt ctt aag tca att aca ggt gtt	441
Gly Ile Val Ala Val Asn Asp Asp Val Leu Lys Ser Ile Thr Gly Val	
120 125 130	
ggg tta gta tcc gac gtg ttc aat gag tca aag ctt gac caa ctc cct	489
Gly Leu Val Ser Asp Val Phe Asn Glu Ser Lys Leu Asp Gln Leu Pro	
135 140 145	
ggg gac atg gca att ggc cac gtc tgg tac tct act gct ggc tct tct	537
Gly Asp Met Ala Ile Gly His Val Trp Tyr Ser Thr Ala Gly Ser Ser	
150 155 160	
atg tta aaa aat gtt cag cct ttt gtt gct aat tat aaa ttt ggg tca	585
Met Leu Lys Asn Val Gln Pro Phe Val Ala Asn Tyr Lys Phe Gly Ser	
165 170 175	
gtt ggt gtt gcc cat aat ggt aat tta gtg aat tat aag tta ctg cgt	633
Val Gly Val Ala His Asn Gly Asn Leu Val Asn Tyr Lys Leu Leu Arg	
180 185 190 195	
ggg gaa cta gaa gag aat ggg tca att ttt aat acg agt tct gat act	681
Gly Glu Leu Glu Glu Asn Gly Ser Ile Phe Asn Thr Ser Ser Asp Thr	
200 205 210	
gaa gtg gta ctt cac ctt att gct ata tcg aaa gct agg cct ttt tta	729
Glu Val Val Leu His Leu Ile Ala Ile Ser Lys Ala Arg Pro Phe Leu	
215 220 225	
ttg agg att gtt gag gct tgt gaa aaa att gaa ggt gct tat tct atg	777
Leu Arg Ile Val Glu Ala Cys Glu Lys Ile Glu Gly Ala Tyr Ser Met	
230 235 240	
gtg ttt gtt act gag gat aag ttg gtt gcc gta agg gat cct cat ggg	825
Val Phe Val Thr Glu Asp Lys Leu Val Ala Val Arg Asp Pro His Gly	
245 250 255	
ttt agg cca ttg gtt atg ggt agg aga agt aat ggt gct gtt gtt ttt	873
Phe Arg Pro Leu Val Met Gly Arg Arg Ser Asn Gly Ala Val Val Phe	
260 265 270 275	

0050/50796

3

gcg tcg gag acg tgt gct ttg gat ttg att gag gct act tat gag agg	921
Ala Ser Glu Thr Cys Ala Leu Asp Leu Ile Glu Ala Thr Tyr Glu Arg	
280 285 290	
gag gtg aat cct ggt gag gtt gtt gtt gtg gat aaa gat ggg gtc cat	969
Glu Val Asn Pro Gly Glu Val Val Val Val Asp Lys Asp Gly Val His	
295 300 305	
tct att tat ttg atg cct cat ccc gag cat aaa tct tgt atc ttt gag	1017
Ser Ile Tyr Leu Met Pro His Pro Glu His Lys Ser Cys Ile Phe Glu	
310 315 320	
cat att tac ttt gct ctg cct aat tcg gtc gtg ttt ggg agg tct gtg	1065
His Ile Tyr Phe Ala Leu Pro Asn Ser Val Val Phe Gly Arg Ser Val	
325 330 335	
tac gag tct agg cgt gct ttt gga gag att ctt gcg act gaa gct ccc	1113
Tyr Glu Ser Arg Arg Ala Phe Gly Glu Ile Leu Ala Thr Glu Ala Pro	
340 345 350 355	
gta gaa tgt gat gtt ggg ata gca gtt cct gat tcg ggt atc gtg gct	1161
Val Glu Cys Asp Val Gly Ile Ala Val Pro Asp Ser Gly Ile Val Ala	
360 365 370	
gcg ctc ggt tat gct gct aaa gcg ggg gta ccg ttt caa caa ggt ttg	1209
Ala Leu Gly Tyr Ala Ala Lys Ala Gly Val Pro Phe Gln Gln Gly Leu	
375 380 385	
ata agg tcg cat tat gtt ggt agg aca ttt atc gag ccg tcg cag aag	1257
Ile Arg Ser His Tyr Val Gly Arg Thr Phe Ile Glu Pro Ser Gln Lys	
390 395 400	
ata agg gat ttc ggg gtg aag ctt aag ttg tca cca gtt agg gca tta	1305
Ile Arg Asp Phe Gly Val Lys Leu Lys Leu Ser Pro Val Arg Ala Leu	
405 410 415	
ttg gag ggg aaa agg gtt gtg gtc gtg gac gat tca atc gtt aga ggg	1353
Leu Glu Gly Lys Arg Val Val Val Val Asp Asp Ser Ile Val Arg Gly	
420 425 430 435	
acg acc tcg tcc aag att gtg agg ttg ttg aag gag gcg ggt gcg aaa	1401
Thr Thr Ser Ser Lys Ile Val Arg Leu Leu Lys Glu Ala Gly Ala Lys	
440 445 450	
gag gtt cat atg agg att gca agc cca cca att ata gct tct tgt tat	1449
Glu Val His Met Arg Ile Ala Ser Pro Pro Ile Ile Ala Ser Cys Tyr	
455 460 465	

4

tat gga gtg gat act cct agt tca gat gag ctg ata tca aat agg atg 1497
 Tyr Gly Val Asp Thr Pro Ser Ser Asp Glu Leu Ile Ser Asn Arg Met
 470 475 480

agt gtg gag gag att aag gag ttc att gga tcg gat tcg ctt gct ttt 1545
 Ser Val Glu Glu Ile Lys Glu Phe Ile Gly Ser Asp Ser Leu Ala Phe
 485 490 495

ctg cca atg gat agc ttg aat aag ttg tta ggc aat gat tct aaa agc 1593
 Leu Pro Met Asp Ser Leu Asn Lys Leu Leu Gly Asn Asp Ser Lys Ser
 500 505 510 515

ttt tgc tat gct tgc ttt tcg ggc aat tac ccg gtc gag ccg acg ggt 1641
 Phe Cys Tyr Ala Cys Phe Ser Gly Asn Tyr Pro Val Glu Pro Thr Gly
 520 525 530

aag gtt aaa agg att ggg gat ttc atg gat gat gga tta agt gga gat 1689
 Lys Val Lys Arg Ile Gly Asp Phe Met Asp Asp Gly Leu Ser Gly Asp
 535 540 545

atg gat tcc att gat ggt ggt tgg cta cca gga agt agt agg gtt caa 1737
 Met Asp Ser Ile Asp Gly Gly Trp Leu Pro Gly Ser Ser Arg Val Gln
 550 555 560

aag act atc ttg aat gaa gtt aga acc ggc taaactttct tttccatggt 1787
 Lys Thr Ile Leu Asn Glu Val Arg Thr Gly
 565 570

tgcttttagtt tttgctttgg atttctaatag cttgactata gaaattataa gtttcaatga 1847
 agtctctttt tctaaaaaaaa aaaaaaaaaa aa 1879

<210> 2

<211> 573

<212> PRT

<213> Nicotiana tabacum

<400> 2

Met Ala Ala Thr Val Ser Thr Ala Ser Ala Ala Ala Thr Asn Lys Ser
 1 5 10 15

Pro Leu Ser Gln Pro Leu Asp Lys Pro Phe Cys Ser Pro Ser Gln Lys
 20 25 30

Leu Leu Ser Leu Ser Pro Lys Thr Leu Pro Lys Pro Tyr Arg Thr Leu
 35 40 45

0050/50796

5

Val Thr Ala Ser Ser Lys Asn Pro Leu Asn Asp Val Val Ser Phe Lys
50 55 60

Lys Ser Ala Asp Asn Thr Leu Asp Ser Tyr Phe Asp Asp Glu Asp Lys
65 70 75 80

Pro Arg Glu Glu Cys Gly Val Val Gly Ile Tyr Gly Asp Ser Glu Ala
85 90 95

Ser Arg Leu Cys Tyr Leu Ala Leu His Ala Leu Leu His Arg Gly Gln
100 105 110

Glu Gly Ala Gly Ile Val Ala Val Asn Asp Asp Val Leu Lys Ser Ile
115 120 125

Thr Gly Val Gly Leu Val Ser Asp Val Phe Asn Glu Ser Lys Leu Asp
130 135 140

Gln Leu Pro Gly Asp Met Ala Ile Gly His Val Trp Tyr Ser Thr Ala
145 150 155 160

Gly Ser Ser Met Leu Lys Asn Val Gln Pro Phe Val Ala Asn Tyr Lys
165 170 175

Phe Gly Ser Val Gly Val Ala His Asn Gly Asn Leu Val Asn Tyr Lys
180 185 190

Leu Leu Arg Gly Glu Leu Glu Glu Asn Gly Ser Ile Phe Asn Thr Ser
195 200 205

Ser Asp Thr Glu Val Val Leu His Leu Ile Ala Ile Ser Lys Ala Arg
210 215 220

Pro Phe Leu Leu Arg Ile Val Glu Ala Cys Glu Lys Ile Glu Gly Ala
225 230 235 240

Tyr Ser Met Val Phe Val Thr Glu Asp Lys Leu Val Ala Val Arg Asp
245 250 255

Pro His Gly Phe Arg Pro Leu Val Met Gly Arg Arg Ser Asn Gly Ala
260 265 270

Val Val Phe Ala Ser Glu Thr Cys Ala Leu Asp Leu Ile Glu Ala Thr
275 280 285

Tyr Glu Arg Glu Val Asn Pro Gly Glu Val Val Val Val Asp Lys Asp
290 295 300

6

Gly	Val	His	Ser	Ile	Tyr	Leu	Met	Pro	His	Pro	Glu	His	Lys	Ser	Cys	
305						310					315					320
Ile	Phe	Glu	His	Ile	Tyr	Phe	Ala	Leu	Pro	Asn	Ser	Val	Val	Phe	Gly	
				325					330					335		
Arg	Ser	Val	Tyr	Glu	Ser	Arg	Arg	Ala	Phe	Gly	Glu	Ile	Leu	Ala	Thr	
			340					345					350			
Glu	Ala	Pro	Val	Glu	Cys	Asp	Val	Gly	Ile	Ala	Val	Pro	Asp	Ser	Gly	
		355					360					365				
Ile	Val	Ala	Ala	Leu	Gly	Tyr	Ala	Ala	Lys	Ala	Gly	Val	Pro	Phe	Gln	
	370					375						380				
Gln	Gly	Leu	Ile	Arg	Ser	His	Tyr	Val	Gly	Arg	Thr	Phe	Ile	Glu	Pro	
385					390					395					400	
Ser	Gln	Lys	Ile	Arg	Asp	Phe	Gly	Val	Lys	Leu	Lys	Leu	Ser	Pro	Val	
				405					410					415		
Arg	Ala	Leu	Leu	Glu	Gly	Lys	Arg	Val	Val	Val	Val	Asp	Asp	Ser	Ile	
			420					425						430		
Val	Arg	Gly	Thr	Thr	Ser	Ser	Lys	Ile	Val	Arg	Leu	Leu	Lys	Glu	Ala	
		435					440						445			
Gly	Ala	Lys	Glu	Val	His	Met	Arg	Ile	Ala	Ser	Pro	Pro	Ile	Ile	Ala	
	450					455					460					
Ser	Cys	Tyr	Tyr	Gly	Val	Asp	Thr	Pro	Ser	Ser	Asp	Glu	Leu	Ile	Ser	
465					470					475					480	
Asn	Arg	Met	Ser	Val	Glu	Glu	Ile	Lys	Glu	Phe	Ile	Gly	Ser	Asp	Ser	
				485					490					495		
Leu	Ala	Phe	Leu	Pro	Met	Asp	Ser	Leu	Asn	Lys	Leu	Leu	Gly	Asn	Asp	
			500					505					510			
Ser	Lys	Ser	Phe	Cys	Tyr	Ala	Cys	Phe	Ser	Gly	Asn	Tyr	Pro	Val	Glu	
		515					520					525				
Pro	Thr	Gly	Lys	Val	Lys	Arg	Ile	Gly	Asp	Phe	Met	Asp	Asp	Gly	Leu	
	530					535					540					
Ser	Gly	Asp	Met	Asp	Ser	Ile	Asp	Gly	Gly	Trp	Leu	Pro	Gly	Ser	Ser	
545					550					555					560	


```
<220>  
<221> CDS  
<222> (25)..(1743)
```

<400> 3																
ctgtcctcat	ttttcccacc	accc	atg	gcc	gcc	acc	gtc	tcc	acc	gcc	tct					51
			Met	Ala	Ala	Thr	Val	Ser	Thr	Ala	Ser					
			1					5								
gcc	gcc	gcc	acc	aac	aaa	tat	cct	ctt	tca	cag	ccc	ctt	gac	aaa	ccc	99
Ala	Ala	Ala	Thr	Asn	Lys	Tyr	Pro	Leu	Ser	Gln	Pro	Leu	Asp	Lys	Pro	
10					15					20					25	
ttt	tgc	tcc	cta	tct	caa	aag	ctc	tta	tct	tta	tcc	cct	aaa	acc	cat	147
Phe	Cys	Ser	Leu	Ser	Gln	Lys	Leu	Leu	Ser	Leu	Ser	Pro	Lys	Thr	His	
				30					35					40		
cct	aaa	ccc	tac	aga	act	ctc	atc	acc	gcc	tct	tcc	aaa	aac	ccc	tta	195
Pro	Lys	Pro	Tyr	Arg	Thr	Leu	Ile	Thr	Ala	Ser	Ser	Lys	Asn	Pro	Leu	
			45					50					55			
aac	gac	gtc	att	tcg	ttt	aag	aaa	tca	gct	gac	aat	acc	ttg	gac	tcc	243
Asn	Asp	Val	Ile	Ser	Phe	Lys	Lys	Ser	Ala	Asp	Asn	Thr	Leu	Asp	Ser	
		60					65					70				
tat	ttt	gac	gat	gac	gat	aaa	ccc	cgt	gaa	gag	tgc	ggc	gtt	gtg	ggc	291
Tyr	Phe	Asp	Asp	Asp	Asp	Lys	Pro	Arg	Glu	Glu	Cys	Gly	Val	Val	Gly	
	75					80					85					
atc	tat	ggc	gac	tca	gaa	gct	tca	cgc	ctt	tgc	tat	tta	gca	ctt	cac	339
Ile	Tyr	Gly	Asp	Ser	Glu	Ala	Ser	Arg	Leu	Cys	Tyr	Leu	Ala	Leu	His	
90					95					100					105	
gcg	ctt	caa	cac	cgt	ggc	caa	gaa	ggc	gcc	ggc	att	gtc	gcc	gtt	aac	387
Ala	Leu	Gln	His	Arg	Gly	Gln	Glu	Gly	Ala	Gly	Ile	Val	Ala	Val	Asn	
				110					115					120		
gac	gac	gtt	ctt	aag	tca	att	aca	ggt	ggt	ggg	tta	gta	tcc	gac	gtg	435
Asp	Asp	Val	Leu	Lys	Ser	Ile	Thr	Gly	Val	Gly	Leu	Val	Ser	Asp	Val	
			125					130					135			

ttc aat gag tca aag ctt gac caa ctc cct ggt gac atg gca att ggc	483
Phe Asn Glu Ser Lys Leu Asp Gln Leu Pro Gly Asp Met Ala Ile Gly	
140 145 150	
cac gta agg tac tct act gct ggc tct tct atg tta aaa aat gtt cag	531
His Val Arg Tyr Ser Thr Ala Gly Ser Ser Met Leu Lys Asn Val Gln	
155 160 165	
cct ttt gtt gct agt tat aaa ttt ggg tca gtt ggt gtt gcc cat aat	579
Pro Phe Val Ala Ser Tyr Lys Phe Gly Ser Val Gly Val Ala His Asn	
170 175 180 185	
ggt aat tta gtg aat tat aag tta ctg cgt agt gaa cta gag gaa aat	627
Gly Asn Leu Val Asn Tyr Lys Leu Leu Arg Ser Glu Leu Glu Glu Asn	
190 195 200	
ggg tca att ttt aat aca agt tct gat act gag gtt gta ctt cac ctt	675
Gly Ser Ile Phe Asn Thr Ser Ser Asp Thr Glu Val Val Leu His Leu	
205 210 215	
att gct ata tct aaa gct agg cca ttt tta ttg agg att gtt gag gct	723
Ile Ala Ile Ser Lys Ala Arg Pro Phe Leu Leu Arg Ile Val Glu Ala	
220 225 230	
tgt gaa aaa att gaa ggt gct tat tct atg gtg ttt gtt act gag gat	771
Cys Glu Lys Ile Glu Gly Ala Tyr Ser Met Val Phe Val Thr Glu Asp	
235 240 245	
aag ttg gtt gcc gta agg gat cct cat ggg ttt agg cca ttg gtt atg	819
Lys Leu Val Ala Val Arg Asp Pro His Gly Phe Arg Pro Leu Val Met	
250 255 260 265	
ggt agg aga agt aat ggt gct gtt gtt ttc gcg tct gag acg tgt gct	867
Gly Arg Arg Ser Asn Gly Ala Val Val Phe Ala Ser Glu Thr Cys Ala	
270 275 280	
ttg gat ttg att gag gct act tat gag agg gag gtg aat cct ggt gag	915
Leu Asp Leu Ile Glu Ala Thr Tyr Glu Arg Glu Val Asn Pro Gly Glu	
285 290 295	
gtt gtt gtt gtg gat aaa gat ggg gtt cag tct att tgt ttg atg cct	963
Val Val Val Val Asp Lys Asp Gly Val Gln Ser Ile Cys Leu Met Pro	
300 305 310	
cat cct gag cgt aaa tct tgt atc ttt gag cat att tac ttt gct ctg	1011
His Pro Glu Arg Lys Ser Cys Ile Phe Glu His Ile Tyr Phe Ala Leu	
315 320 325	

10

tcg ggc aat tac cca gtc gag ccg acg ggt aag gtt aaa agg ata ggg 1635
 Ser Gly Asn Tyr Pro Val Glu Pro Thr Gly Lys Val Lys Arg Ile Gly
 525 530 535

gat ttc atg gat gat gga tta agt gga gat atg gat tcc att gat ggt 1683
 Asp Phe Met Asp Asp Gly Leu Ser Gly Asp Met Asp Ser Ile Asp Gly
 540 545 550

gga tgg cta cca gga agt agt agg gtt caa aag act atc ttg aat gaa 1731
 Gly Trp Leu Pro Gly Ser Ser Arg Val Gln Lys Thr Ile Leu Asn Glu
 555 560 565

gtt aga acc agc taaactttct ttccatggt tgcttttagtt ttgcttttg 1783
 Val Arg Thr Ser
 570

atttctaattg cttgaccata gaaattataa gtttcaatga agtctctttt tctatttgga 1843

atgccacatg attctactga tctatg 1869

<210> 4

<211> 573

<212> PRT

<213> Nicotiana tabacum

<400> 4

Met Ala Ala Thr Val Ser Thr Ala Ser Ala Ala Ala Thr Asn Lys Tyr
 1 5 10 15

Pro Leu Ser Gln Pro Leu Asp Lys Pro Phe Cys Ser Leu Ser Gln Lys
 20 25 30

Leu Leu Ser Leu Ser Pro Lys Thr His Pro Lys Pro Tyr Arg Thr Leu
 35 40 45

Ile Thr Ala Ser Ser Lys Asn Pro Leu Asn Asp Val Ile Ser Phe Lys
 50 55 60

Lys Ser Ala Asp Asn Thr Leu Asp Ser Tyr Phe Asp Asp Asp Asp Lys
 65 70 75 80

Pro Arg Glu Glu Cys Gly Val Val Gly Ile Tyr Gly Asp Ser Glu Ala
 85 90 95

Ser Arg Leu Cys Tyr Leu Ala Leu His Ala Leu Gln His Arg Gly Gln
 100 105 110

11

Glu	Gly	Ala	Gly	Ile	Val	Ala	Val	Asn	Asp	Asp	Val	Leu	Lys	Ser	Ile	115	120	125	
Thr	Gly	Val	Gly	Leu	Val	Ser	Asp	Val	Phe	Asn	Glu	Ser	Lys	Leu	Asp	130	135	140	
Gln	Leu	Pro	Gly	Asp	Met	Ala	Ile	Gly	His	Val	Arg	Tyr	Ser	Thr	Ala	145	150	155	160
Gly	Ser	Ser	Met	Leu	Lys	Asn	Val	Gln	Pro	Phe	Val	Ala	Ser	Tyr	Lys	165	170	175	
Phe	Gly	Ser	Val	Gly	Val	Ala	His	Asn	Gly	Asn	Leu	Val	Asn	Tyr	Lys	180	185	190	
Leu	Leu	Arg	Ser	Glu	Leu	Glu	Glu	Asn	Gly	Ser	Ile	Phe	Asn	Thr	Ser	195	200	205	
Ser	Asp	Thr	Glu	Val	Val	Leu	His	Leu	Ile	Ala	Ile	Ser	Lys	Ala	Arg	210	215	220	
Pro	Phe	Leu	Leu	Arg	Ile	Val	Glu	Ala	Cys	Glu	Lys	Ile	Glu	Gly	Ala	225	230	235	240
Tyr	Ser	Met	Val	Phe	Val	Thr	Glu	Asp	Lys	Leu	Val	Ala	Val	Arg	Asp	245	250	255	
Pro	His	Gly	Phe	Arg	Pro	Leu	Val	Met	Gly	Arg	Arg	Ser	Asn	Gly	Ala	260	265	270	
Val	Val	Phe	Ala	Ser	Glu	Thr	Cys	Ala	Leu	Asp	Leu	Ile	Glu	Ala	Thr	275	280	285	
Tyr	Glu	Arg	Glu	Val	Asn	Pro	Gly	Glu	Val	Val	Val	Val	Asp	Lys	Asp	290	295	300	
Gly	Val	Gln	Ser	Ile	Cys	Leu	Met	Pro	His	Pro	Glu	Arg	Lys	Ser	Cys	305	310	315	320
Ile	Phe	Glu	His	Ile	Tyr	Phe	Ala	Leu	Pro	Asn	Ser	Val	Val	Phe	Gly	325	330	335	
Arg	Ser	Val	Tyr	Glu	Ser	Arg	Arg	Ala	Phe	Gly	Glu	Ile	Leu	Ala	Thr	340	345	350	
Glu	Ala	Pro	Val	Glu	Cys	Asp	Val	Val	Ile	Ala	Val	Pro	Asp	Ser	Gly	355	360	365	

Ser Gln Lys Ile Arg Asp Phe Gly Val Lys Leu Lys Leu Ser Pro Val
405 410 415

Val	Arg	Gly	Thr	Thr	Ser	Ser	Lys	Ile	Val	Arg	Leu	Leu	Lys	Glu	Ala
		435					440					445			

Ser Cys Tyr Tyr Gly Val Asp Thr Pro Ser Ser Asp Glu Leu Ile Ser
465 470 475 480

Leu Ala Phe Leu Pro Met Asp Ser Leu Asn Lys Leu Leu Gly Asn Asp
500 505 510

Pro Thr Gly Lys Val Lys Arg Ile Gly Asp Phe Met Asp Asp Gly Leu
530 535 540

Arg Val Gln Lys Thr Ile Leu Asn Glu Val Arg Thr Ser
565 570